Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer
暂无分享,去创建一个
Ying Feng | Pan Tong | Robert J. Cardnell | Lauren Averett Byers | Ignacio Wistuba | John V. Heymach | Jing Wang | Leonard E. Post | Don L. Gibbons | Jing Wang | I. Wistuba | J. Fujimoto | L. Byers | D. Gibbons | P. Tong | C. Gay | L. Post | T. Sen | Ying Feng | Youhong Fan | Y. Ru | Junya Fujimoto | R. Cardnell | Bonnie S. Glisson | B. Glisson | Yuanbin Ru | C. Stewart | Yuqiao Shen | Fatemah Masrorpour | Triparna Sen | Lerong Li | C. Allison Stewart | Carl M. Gay | You Fan | Rasha O. Bara | Samrat T. Kundu | Karen Yu | Yuqiao Shen | S. Kundu | Lerong Li | K. Yu | Fatemah Masrorpour | J. Heymach | C. A. Stewart | Rasha O Bara | Leonard E. Post
[1] K. Cibulskis,et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer , 2012, Nature Genetics.
[2] Y. Hu,et al. Schlafen-11 sensitizes colorectal carcinoma cells to irinotecan , 2014, Anti-cancer drugs.
[3] R. Bourgon,et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial , 2016, The Lancet.
[4] Sun-Mi Park,et al. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. , 2008, Genes & development.
[5] C. Rudin,et al. PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer , 2016, Clinical Cancer Research.
[6] W. Reinhold,et al. Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents , 2012, Proceedings of the National Academy of Sciences.
[7] W. Reinhold,et al. Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs , 2015, Oncotarget.
[8] D. Blaas,et al. Expression and regulation of Schlafen (SLFN) family members in primary human monocytes, monocyte-derived dendritic cells and T cells , 2015, Results in immunology.
[9] A. Behrens,et al. ATM signalling and cancer , 2014, Oncogene.
[10] C. Rudin,et al. Small cell lung cancer: Where do we go from here? , 2015, Cancer.
[11] Takanori Fujita,et al. PRC2 overexpression and PRC2-target gene repression relating to poorer prognosis in small cell lung cancer , 2013, Scientific Reports.
[12] Lixia Diao,et al. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumor cell PD-L1 expression and intratumoral immunosuppression , 2014, Nature Communications.
[13] K. Tewari,et al. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors , 2016, Current Treatment Options in Oncology.
[14] Luc Girard,et al. ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic Programs. , 2016, Cell reports.
[15] C. Rice,et al. Interferon-stimulated genes: a complex web of host defenses. , 2014, Annual review of immunology.
[16] Ying Feng,et al. Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP Inhibitor BMN 673 in Small Cell Lung Cancer , 2013, Clinical Cancer Research.
[17] S. Knudsen,et al. Evaluation of microRNA expression profiles that may predict recurrence of localized stage I non-small cell lung cancer after surgical resection. , 2010, Cancer research.
[18] A. Monks,et al. Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA Expression. , 2016, Journal of the National Cancer Institute.
[19] Kevin R. Coombes,et al. The Bimodality Index: A Criterion for Discovering and Ranking Bimodal Signatures from Cancer Gene Expression Profiling Data , 2009, Cancer informatics.
[20] I. Huijbers,et al. Rapid target gene validation in complex cancer mouse models using re-derived embryonic stem cells , 2014, EMBO molecular medicine.
[21] Z. Madjd,et al. Differential Expression of Cancer Stem Cell Markers ALDH1 and CD133 in Various Lung Cancer Subtypes , 2015, Cancer investigation.
[22] Martin Vingron,et al. Comprehensive genomic profiles of small cell lung cancer , 2015, Nature.
[23] Adam A. Margolin,et al. The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.
[24] M. Pysz,et al. Initiation and Characterization of Small Cell Lung Cancer Patient-Derived Xenografts from Ultrasound-Guided Transbronchial Needle Aspirates , 2015, PloS one.
[25] P. Meltzer,et al. SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma , 2015, Clinical Cancer Research.
[26] M. Weitzman,et al. Codon-usage-based inhibition of HIV protein synthesis by human schlafen 11 , 2012, Nature.
[27] Junjie Chen,et al. SLFN11 inhibits checkpoint maintenance and homologous recombination repair , 2016, EMBO reports.
[28] J. Sage,et al. Identification and Targeting of Long-Term Tumor-Propagating Cells in Small Cell Lung Cancer. , 2016, Cell reports.
[29] Alex M. Fichtenholtz,et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing , 2013, Nature Biotechnology.
[30] Alan Ashworth,et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. , 2006, Cancer research.
[31] G. Mills,et al. An Integrated Molecular Analysis of Lung Adenocarcinomas Identifies Potential Therapeutic Targets among TTF1-Negative Tumors, Including DNA Repair Proteins and Nrf2 , 2015, Clinical Cancer Research.
[32] G. Hannon,et al. Patient-derived tumor xenografts: transforming clinical samples into mouse models. , 2013, Cancer research.
[33] J. Sage,et al. Identification and Targeting of Long-Term Tumor-Propagating Cells in Small Cell Lung Cancer. , 2016, Cell reports.
[34] Robert Gentleman,et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer , 2012, Nature Genetics.
[35] Thomas Helleday,et al. The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings , 2011, Molecular oncology.
[36] Wei Yuan,et al. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. , 2015, The New England journal of medicine.
[37] D. Jäger,et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. , 2016, The Lancet. Oncology.
[38] Michael Peyton,et al. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. , 2012, Cancer discovery.
[39] D. Lim,et al. Evaluation of the methods to identify patients who may benefit from PARP inhibitor use. , 2016, Endocrine-related cancer.
[40] Y. Pommier,et al. Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. , 2012, Cancer research.
[41] Jaime Rodriguez-Canales,et al. A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition , 2015, Clinical Cancer Research.